Utilizing Patient Support Services

Conference Correspondent - TON - ASH 2015 - Multiple Myeloma, Conference Correspondent
Beth Faiman, PhD, APRN-BC, AOCN
Editor in Chief

Beth Faiman argues that patient support services are integral in her role as a nurse because they aid in getting patients the treatments they need, promote adherence, and provide patient education.

Patient support services are really important to our patients with multiple myeloma. I all ready mentioned that when you have the right drug for the right patient, one of the challenges is actually getting that drug to the patient, and having them understand how to take it. This is a specific concern with the oral oncolytics, because the high copays that might be involved, et cetera.

The patient support services are really intrical because there are people within each pharmacy and each pharma company that are dedicated to help get the drugs to the patients that need them.

I think that that helps me as a nurse in the clinic so much to have those resources for our patients. Not only getting the drugs there, but providing education, helping with adherence and facilitating refills. These are all very important to the improved care of our patients.

Related Items
Staying Abreast of New Treatments
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent published on April 18, 2017 in ASH 2016 - Multiple Myeloma, Hematologic Cancers, Conference Correspondent
Managing Patients with Multiple Myeloma
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent published on April 18, 2017 in ASH 2016 - Multiple Myeloma, Hematologic Cancers, Conference Correspondent
Perceptions of Daratumumab Therapy
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent published on April 18, 2017 in ASH 2016 - Multiple Myeloma, Hematologic Cancers, Conference Correspondent
Starting a Patient on Daratumumab
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent published on April 18, 2017 in ASH 2016 - Multiple Myeloma, Hematologic Cancers, Conference Correspondent
What Do Patients Ask About Daratumumab?
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent published on April 18, 2017 in ASH 2016 - Multiple Myeloma, Hematologic Cancers, Conference Correspondent
Unmet Needs in Patients with Myeloma
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent published on April 18, 2017 in ASH 2016 - Multiple Myeloma, Hematologic Cancers, Conference Correspondent
The Challenge of Managing Treatment-Related Toxicites
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent published on April 18, 2017 in ASH 2016 - Multiple Myeloma, Hematologic Cancers, Conference Correspondent
Self-Managing Side Effects
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent published on April 18, 2017 in ASH 2016 - Multiple Myeloma, Hematologic Cancers, Conference Correspondent
Concerns Over New Multiple Myeloma Therapies
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent published on April 18, 2017 in ASH 2016 - Multiple Myeloma, Hematologic Cancers, Conference Correspondent
How Janssen CarePath Helps Patients
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent published on April 18, 2017 in ASH 2016 - Multiple Myeloma, Hematologic Cancers, Conference Correspondent
Last modified: February 10, 2016